Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 3Phase 2 2

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 21Other solid neoplasm 4Thoracic 3Head & Neck 3Gynecologic 3Other hematologic neoplasm 2Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Solid Tumors Refractory to Standard Therapy 1Solid Tumors 1Solid Tumor, Adult 1Advanced Solid Tumors 1

Interventions

pembrolizumab 41Injections 39toripalimab 23Nivolumab 22Cisplatin 19Pemetrexed 18Carboplatin 18Cyclophosphamide 17Paclitaxel 14Bevacizumab 14fludarabine 12Gemcitabine 11tislelizumab 10Ipilimumab 10spartalizumab 9Irinotecan 9atezolizumab 8Docetaxel 8Oxaliplatin 7Leucovorin 7Fluorouracil 7Capecitabine 6sintilimab 5Interleukin-2 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 4sotorasib 4pazopanib 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × palbociclib × Other solid neoplasm × Clear all
NCT06736704 2026-03-13

SNV4818 in Participants With Advanced Solid Tumors

Pikavation Therapeutics, Inc.

Phase 1/2 Recruiting
320 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06940349 2025-04-23

COPS-01

Rabin Medical Center

Phase 1/2 Recruiting
100 enrolled
Other solid neoplasm

Solid Tumors Refractory to Standard Therapy

NCT06895733 2025-03-26

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Tianjin Medical University Second Hospital

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Calithera Biosciences, Inc

Phase 1/2 Completed
53 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡